Open access
Sep 2026
Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer.
Clinical benefit with perioperative durvalumab plus neoadjuvant chemotherapy plus durvalumab or placebo before surgery followed by adjuvant durvalumab or placebo was generally maintained across the surgery subgroups.
David H. Harpole, J. Heymach, M. Reck et al.
· Journal of Thoracic and Card... · 0 citations